Annual EBITDA
-$3.82 M
+$22.62 M+85.54%
December 31, 2023
Summary
- As of February 12, 2025, SBFM annual EBITDA is -$3.82 million, with the most recent change of +$22.62 million (+85.54%) on December 31, 2023.
- During the last 3 years, SBFM annual EBITDA has fallen by -$1.22 million (-46.98%).
- SBFM annual EBITDA is now -29093.89% below its all-time high of -$13.10 thousand, reached on July 1, 2007.
Performance
SBFM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$918.00 K
-$131.10 K-16.66%
September 30, 2024
Summary
- As of February 12, 2025, SBFM quarterly EBITDA is -$918.00 thousand, with the most recent change of -$131.10 thousand (-16.66%) on September 30, 2024.
- Over the past year, SBFM quarterly EBITDA has dropped by -$383.20 thousand (-71.65%).
- SBFM quarterly EBITDA is now -229.86% below its all-time high of $706.90 thousand, reached on December 1, 2021.
Performance
SBFM Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$3.83 M
-$383.20 K-11.11%
September 30, 2024
Summary
- As of February 12, 2025, SBFM TTM EBITDA is -$3.83 million, with the most recent change of -$383.20 thousand (-11.11%) on September 30, 2024.
- Over the past year, SBFM TTM EBITDA has increased by +$22.29 million (+85.33%).
- SBFM TTM EBITDA is now -43443.18% below its all-time high of -$8800.00, reached on October 1, 2007.
Performance
SBFM TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SBFM EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +85.5% | -71.7% | +85.3% |
| 3 y3 years | -47.0% | -18.3% | +85.8% |
| 5 y5 years | -96.6% | -18.3% | +85.8% |
SBFM EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +85.5% | -229.9% | +96.0% | -52.9% | +85.8% |
| 5 y | 5-year | -303.3% | +85.5% | -229.9% | +96.0% | -339.6% | +85.8% |
| alltime | all time | <-9999.0% | +85.5% | -229.9% | +96.0% | <-9999.0% | +85.8% |
Sunshine Biopharma EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$918.00 K(+16.7%) | -$3.83 M(+11.1%) |
| Jun 2024 | - | -$786.90 K(-32.7%) | -$3.45 M(+0.3%) |
| Mar 2024 | - | -$1.17 M(+22.2%) | -$3.44 M(-10.7%) |
| Dec 2023 | -$3.82 M(-85.5%) | -$957.30 K(+79.0%) | -$3.85 M(-85.3%) |
| Sep 2023 | - | -$534.80 K(-31.1%) | -$26.12 M(-3.4%) |
| Jun 2023 | - | -$776.20 K(-50.9%) | -$27.05 M(+0.9%) |
| Mar 2023 | - | -$1.58 M(-93.2%) | -$26.81 M(+1.4%) |
| Dec 2022 | -$26.45 M(+118.7%) | -$23.23 M(+1495.5%) | -$26.45 M(+955.2%) |
| Sep 2022 | - | -$1.46 M(+171.4%) | -$2.51 M(-50.3%) |
| Jun 2022 | - | -$536.60 K(-56.0%) | -$5.04 M(-29.8%) |
| Mar 2022 | - | -$1.22 M(-272.6%) | -$7.18 M(-40.6%) |
| Dec 2021 | -$12.09 M(+364.8%) | - | - |
| Dec 2021 | - | $706.90 K(-117.7%) | -$12.09 M(-12.2%) |
| Sep 2021 | - | -$3.99 M(+48.8%) | -$13.78 M(+31.7%) |
| Jun 2021 | - | -$2.68 M(-56.3%) | -$10.46 M(+20.8%) |
| Mar 2021 | - | -$6.13 M(+529.1%) | -$8.66 M(+232.9%) |
| Dec 2020 | -$2.60 M(+174.3%) | -$974.80 K(+44.8%) | -$2.60 M(+30.3%) |
| Sep 2020 | - | -$673.00 K(-23.5%) | -$2.00 M(+21.6%) |
| Jun 2020 | - | -$879.70 K(+1087.2%) | -$1.64 M(+88.4%) |
| Mar 2020 | - | -$74.10 K(-80.0%) | -$871.70 K(-6.8%) |
| Dec 2019 | -$948.40 K(-51.2%) | -$369.70 K(+15.9%) | -$935.30 K(+8.6%) |
| Sep 2019 | - | -$318.90 K(+192.6%) | -$861.20 K(-38.4%) |
| Jun 2019 | - | -$109.00 K(-20.8%) | -$1.40 M(-26.8%) |
| Mar 2019 | - | -$137.70 K(-53.4%) | -$1.91 M(-2.3%) |
| Dec 2018 | -$1.95 M(+109.4%) | -$295.60 K(-65.5%) | -$1.96 M(+8.0%) |
| Sep 2018 | - | -$856.20 K(+37.6%) | -$1.81 M(+69.0%) |
| Jun 2018 | - | -$622.10 K(+239.2%) | -$1.07 M(+15.9%) |
| Mar 2018 | - | -$183.40 K(+21.5%) | -$926.00 K(-0.3%) |
| Dec 2017 | -$928.80 K(-72.7%) | -$151.00 K(+29.8%) | -$928.60 K(-50.6%) |
| Sep 2017 | - | -$116.30 K(-75.5%) | -$1.88 M(-43.4%) |
| Jun 2017 | - | -$475.30 K(+155.5%) | -$3.32 M(+0.6%) |
| Mar 2017 | - | -$186.00 K(-83.1%) | -$3.30 M(-2.9%) |
| Dec 2016 | -$3.40 M | -$1.10 M(-29.2%) | -$3.40 M(+26.7%) |
| Sep 2016 | - | -$1.56 M(+241.5%) | -$2.68 M(+103.6%) |
| Jun 2016 | - | -$456.40 K(+61.2%) | -$1.32 M(-2.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2016 | - | -$283.10 K(-26.5%) | -$1.35 M(+13.3%) |
| Dec 2015 | -$1.34 M(-25.2%) | -$385.40 K(+99.6%) | -$1.19 M(+3.6%) |
| Sep 2015 | - | -$193.10 K(-60.1%) | -$1.15 M(-6.8%) |
| Jun 2015 | - | -$484.30 K(+288.1%) | -$1.23 M(-13.1%) |
| Mar 2015 | - | -$124.80 K(-63.8%) | -$1.42 M(-16.6%) |
| Dec 2014 | -$1.79 M(-27.8%) | -$344.50 K(+24.2%) | -$1.70 M(-16.7%) |
| Sep 2014 | - | -$277.40 K(-58.6%) | -$2.04 M(+5.1%) |
| Jun 2014 | - | -$670.10 K(+65.1%) | -$1.94 M(+36.4%) |
| Mar 2014 | - | -$405.90 K(-40.8%) | -$1.42 M(-42.9%) |
| Dec 2013 | -$2.48 M(+251.6%) | -$685.40 K(+285.7%) | -$2.49 M(+25.0%) |
| Sep 2013 | - | -$177.70 K(+16.4%) | -$1.99 M(-9.1%) |
| Jun 2013 | - | -$152.60 K(-89.6%) | -$2.19 M(+2.3%) |
| Mar 2013 | - | -$1.47 M(+681.6%) | -$2.14 M(+202.7%) |
| Dec 2012 | -$706.70 K(+27.1%) | -$188.30 K(-50.0%) | -$706.70 K(-20.6%) |
| Sep 2012 | - | -$376.40 K(+266.5%) | -$890.50 K(+41.2%) |
| Jun 2012 | - | -$102.70 K(+161.3%) | -$630.50 K(+15.8%) |
| Mar 2012 | - | -$39.30 K(-89.4%) | -$544.30 K(-1.8%) |
| Dec 2011 | -$556.20 K(+3.5%) | -$372.10 K(+219.7%) | -$554.20 K(-9.0%) |
| Sep 2011 | - | -$116.40 K(+605.5%) | -$609.00 K(-6.7%) |
| Jun 2011 | - | -$16.50 K(-66.5%) | -$653.00 K(-70.6%) |
| Mar 2011 | - | -$49.20 K(-88.5%) | -$2.22 M(+0.7%) |
| Dec 2010 | -$537.40 K(+437.4%) | -$426.90 K(+166.1%) | -$2.21 M(+23.9%) |
| Sep 2010 | - | -$160.40 K(-89.9%) | -$1.78 M(+7.8%) |
| Jun 2010 | - | -$1.59 M(+4489.9%) | -$1.65 M(+2204.6%) |
| Mar 2010 | - | -$34.60 K(+8.1%) | -$71.80 K(+66.6%) |
| Dec 2009 | -$100.00 K(+536.9%) | - | - |
| Oct 2009 | - | -$32.00 K(+515.4%) | -$43.10 K(+174.5%) |
| Jul 2009 | -$15.70 K(-39.8%) | -$5200.00(+108.0%) | -$15.70 K(+6.8%) |
| Apr 2009 | - | -$2500.00(-26.5%) | -$14.70 K(-36.1%) |
| Jan 2009 | - | -$3400.00(-26.1%) | -$23.00 K(+5.0%) |
| Oct 2008 | - | -$4600.00(+9.5%) | -$21.90 K(-16.1%) |
| Jul 2008 | -$26.10 K(+99.2%) | -$4200.00(-61.1%) | -$26.10 K(+19.2%) |
| Apr 2008 | - | -$10.80 K(+369.6%) | -$21.90 K(+97.3%) |
| Jan 2008 | - | -$2300.00(-73.9%) | -$11.10 K(+26.1%) |
| Oct 2007 | - | -$8800.00 | -$8800.00 |
| Jul 2007 | -$13.10 K | - | - |
FAQ
- What is Sunshine Biopharma annual EBITDA?
- What is the all time high annual EBITDA for Sunshine Biopharma?
- What is Sunshine Biopharma annual EBITDA year-on-year change?
- What is Sunshine Biopharma quarterly EBITDA?
- What is the all time high quarterly EBITDA for Sunshine Biopharma?
- What is Sunshine Biopharma quarterly EBITDA year-on-year change?
- What is Sunshine Biopharma TTM EBITDA?
- What is the all time high TTM EBITDA for Sunshine Biopharma?
- What is Sunshine Biopharma TTM EBITDA year-on-year change?
What is Sunshine Biopharma annual EBITDA?
The current annual EBITDA of SBFM is -$3.82 M
What is the all time high annual EBITDA for Sunshine Biopharma?
Sunshine Biopharma all-time high annual EBITDA is -$13.10 K
What is Sunshine Biopharma annual EBITDA year-on-year change?
Over the past year, SBFM annual EBITDA has changed by +$22.62 M (+85.54%)
What is Sunshine Biopharma quarterly EBITDA?
The current quarterly EBITDA of SBFM is -$918.00 K
What is the all time high quarterly EBITDA for Sunshine Biopharma?
Sunshine Biopharma all-time high quarterly EBITDA is $706.90 K
What is Sunshine Biopharma quarterly EBITDA year-on-year change?
Over the past year, SBFM quarterly EBITDA has changed by -$383.20 K (-71.65%)
What is Sunshine Biopharma TTM EBITDA?
The current TTM EBITDA of SBFM is -$3.83 M
What is the all time high TTM EBITDA for Sunshine Biopharma?
Sunshine Biopharma all-time high TTM EBITDA is -$8800.00
What is Sunshine Biopharma TTM EBITDA year-on-year change?
Over the past year, SBFM TTM EBITDA has changed by +$22.29 M (+85.33%)